Denali Therapeutics Target of Unusually Large Options Trading (NASDAQ:DNLI)

view original post

Denali Therapeutics Inc. (NASDAQ:DNLI) was the target of unusually large options trading on Wednesday. Stock investors purchased 6,099 put options on the company. This is an increase of 2,484% compared to the typical daily volume of 236 put options.

Several equities research analysts have recently issued reports on the stock. Oppenheimer assumed coverage on shares of Denali Therapeutics in a research note on Monday, September 20th. They set an “outperform” rating and a $85.00 target price on the stock. Evercore ISI upped their price target on shares of Denali Therapeutics from $70.00 to $111.00 and gave the stock an “outperform” rating in a research report on Friday, November 5th. Finally, Zacks Investment Research upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating and set a $49.00 price objective for the company in a report on Friday, November 19th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Buy” and an average target price of $87.75.

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the company’s stock in a transaction on Wednesday, November 10th. The shares were sold at an average price of $52.81, for a total value of $87,981.46. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Alexander O. Schuth sold 10,000 shares of the company’s stock in a transaction on Thursday, November 4th. The shares were sold at an average price of $52.84, for a total transaction of $528,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,502 shares of company stock worth $3,321,874. Insiders own 17.00% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Arizona State Retirement System boosted its position in shares of Denali Therapeutics by 1.3% during the 3rd quarter. Arizona State Retirement System now owns 21,458 shares of the company’s stock valued at $1,083,000 after purchasing an additional 270 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Denali Therapeutics by 30.4% in the third quarter. PNC Financial Services Group Inc. now owns 1,211 shares of the company’s stock worth $61,000 after purchasing an additional 282 shares in the last quarter. Ensign Peak Advisors Inc raised its position in Denali Therapeutics by 0.7% during the second quarter. Ensign Peak Advisors Inc now owns 41,942 shares of the company’s stock valued at $3,290,000 after acquiring an additional 300 shares in the last quarter. Meeder Asset Management Inc. raised its position in Denali Therapeutics by 12.5% during the second quarter. Meeder Asset Management Inc. now owns 2,747 shares of the company’s stock valued at $215,000 after acquiring an additional 306 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new position in Denali Therapeutics during the second quarter valued at approximately $29,000. Institutional investors own 65.90% of the company’s stock.

NASDAQ:DNLI opened at $44.55 on Thursday. The firm has a 50 day simple moving average of $47.22 and a 200-day simple moving average of $53.11. The firm has a market cap of $5.44 billion, a PE ratio of 318.24 and a beta of 1.75. Denali Therapeutics has a 1-year low of $41.10 and a 1-year high of $83.98.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, November 4th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.23). Denali Therapeutics had a return on equity of 2.72% and a net margin of 8.38%. The firm had revenue of $5.29 million during the quarter, compared to analyst estimates of $30.28 million. During the same period last year, the business earned ($0.54) EPS. The firm’s revenue was down 43.7% on a year-over-year basis. Equities analysts expect that Denali Therapeutics will post -2.21 earnings per share for the current year.

About Denali Therapeutics

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Featured Article: Equity Income

Want More Great Investing Ideas?